Background: Gastric cancer (GC) still represents a major health problem, despite a decrease in its incidence in the last few years. Because of the social impact of GC, there is a need for developing novel biomarkers to stratify patients into appropriate screening, surveillance, or treatment programs. Although histopathology remains the most reliable and less-expensive method, numerous efforts have been made toward identifying and validating novel biomarkers. Recent advances in molecular therapy have identified human epidermal growth factor receptor 2 (HER2) as an important target for anticancer therapy in GC. Although the clinical relevance and prognostic significance of HER2 in breast cancer have been well acknowledged, it remains controversial in GC. The aim of this work was to evaluate the role of HER2 as a prognostic factor in patients with GC.
Methods: HER2 expression was investigated in 30 patients with GC by immunohistochemical staining and the results were compared and correlated with clinicopathologic parameters (age, sex, tumor location, histopathological type tumor stage, lymphovascular invasion, and lymph node metastasis).
Results: Among the samples that attained a score of 3+, 85% showed staining in 50% or more of the tumor area, 10% that attained a score of 2+ showed staining in 50% or more of the tumor area, whereas only 5% that attained a score of 1+ showed staining less than 50%. There was no statistically significant correlation between HER2 positivity and age (P=0.0601), sex (P=0.3000), or tumor location (P=0.364). HER2-positive tumors were found more often in lesions located in the lower third of the stomach compared with those located in the upper third (83 vs. 71%). According to Lauren’s classification, HER2 overexpression was more often detected in the intestinal histological type (93%) than in the mixed (83%) or diffuse (67%) type, although this difference was not statistically significant. HER2 positivity was statistically significantly correlated with tumor-node-metastasis stage (P=0.0312) and lymph node metastasis (P=0.009).
Conclusion: HER2 overexpression was positively correlated with aggressive biological behavior and was an independent poor prognostic factor for GCs. Therefore, HER2-positive GCs should be considered for adjuvant trastuzumab therapy.
Department of Pathology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt
Correspondence to Adel R. Hinnis, MD, Department of Pathology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt Tel: +20 122 281 8303; e-mail: email@example.com
Received February 15, 2013
Accepted March 31, 2013